OTC future for canker sore patch?
This article was originally published in The Tan Sheet
Oral canker sore delivery vehicle OraDisc A, "which adheres to the disease site and slowly degrades, releasing the drug locally," eventually could be marketed OTC, Access Pharmaceuticals says. Although firm has been in negotiations with "numerous consumer/pharmaceutical organizations globally" to develop OTC version of oral delivery vehicle for amlexanox, details and timing of such a move remain uncertain, Access says. Final Phase III study for Rx version "has commenced and completion is anticipated by the end of 2002," company notes...
You may also be interested in...
With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.
Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.
Starpharma's COVID-busting Viraleze antiviral nasal spray will soon be available across Europe, included the UK. But will it fall foul of local evidence requirements, for example in France, where the country's medicines agency has halted the sale of Pharma & Beauty (P&B) Group's COV-Defense spray until its efficacy against COVID has been confirmed by human-based studies?